Risk of dependence on Oypalomin sales
First written in FY2017. 1 of 4 entries say "Mitigated", first in FY2020. Latest entry: FY2022.
The whole theme swung hardest in 2024: 13 of 48 companies on the "Worse" side.
29 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「The urinary tract and vascular contrast agent Iopamidol Injection is a core product, accounting for nearly 20% of sales in the fiscal year ended September 2022. If sales of this product were discontinued for an unforeseen reason or declined substantially, this could affect the performance of our Group.」
Regarding reliance on sales of a specific product, continues to disclose Iopamidol Injection as the product concerned, accounting for nearly 20% of sales in the fiscal year ended September 2022. - FY2021ReframedAnnual report
「The urinary tract and vascular contrast agent Iopamidol is a core product, accounting for approximately 20% of sales in the fiscal year ended September 2021.」
Regarding reliance on sales of a specific product, the product identified changed from Oypalomin to Iopamidol, which is described as a core product accounting for approximately 20% of sales. - FY2020MitigatedAnnual report
「The urinary tract and vascular contrast agent Oypalomin is a core product, accounting for approximately 20% of sales in the fiscal year ended September 2020. We are implementing measures to prevent discontinuation of sales, including placing the SCM Department under the direct supervision of the President to strengthen supply chain management and introducing quality management reviews for quality control. We also expect reliance on specific products to decline as we expand our product portfolio, including new products scheduled for launch.」
While reliance on Oypalomin sales remains at approximately 20%, describes placing the SCM Department under the direct supervision of the President, introducing quality management reviews, and expanding the product portfolio as measures. - FY2017First statedAnnual report
「The urinary tract and vascular contrast agent Oypalomin is a core product, accounting for approximately 20% of sales in the fiscal year ended September 2017. If sales of this product were discontinued for an unforeseen reason or declined substantially, this could affect the performance of our Group.」
Describes the fact that core product Oypalomin accounts for approximately 20% of sales for the fiscal year and the impact of discontinuation or a decline in sales.